HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David M Goldenberg Selected Research

milatuzumab

1/2021Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).
6/2015The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
11/2013Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
6/2013Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
1/2013Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
1/2013Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
4/2012Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
3/2012The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
12/2011FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
4/2011Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David M Goldenberg Research Topics

Disease

193Neoplasms (Cancer)
01/2021 - 01/2002
47Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2015 - 05/2002
36Lymphoma (Lymphomas)
01/2015 - 05/2002
21Neoplasm Metastasis (Metastasis)
01/2021 - 02/2002
15Colorectal Neoplasms (Colorectal Cancer)
12/2019 - 02/2002
15Pancreatic Neoplasms (Pancreatic Cancer)
09/2015 - 05/2002
13Colonic Neoplasms (Colon Cancer)
06/2018 - 04/2005
12Carcinoma (Carcinomatosis)
08/2018 - 06/2002
12B-Cell Lymphoma (Lymphoma, B Cell)
10/2013 - 05/2002
11Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021 - 01/2006
9Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 01/2002
9Multiple Myeloma
01/2018 - 10/2004
9Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2018 - 08/2008
9Hematologic Neoplasms (Hematological Malignancy)
07/2015 - 05/2002
8Triple Negative Breast Neoplasms
01/2021 - 03/2014
8Breast Neoplasms (Breast Cancer)
11/2020 - 03/2004
8B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2018 - 08/2007
8Adenocarcinoma
09/2015 - 12/2007
8Prostatic Neoplasms (Prostate Cancer)
02/2015 - 01/2007
7Autoimmune Diseases (Autoimmune Disease)
01/2014 - 10/2006
6medullary Thyroid cancer
11/2020 - 12/2004
6Leukemia
01/2014 - 09/2008
5Neutropenia
01/2021 - 06/2011
5Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2018 - 08/2004
5Neoplasm Micrometastasis
01/2017 - 10/2003
5Burkitt Lymphoma (Burkitt's Lymphoma)
01/2015 - 12/2005
5Renal Cell Carcinoma (Grawitz Tumor)
04/2013 - 09/2003
4Diarrhea
01/2021 - 09/2015
4Disease Progression
01/2021 - 06/2010
4Body Weight (Weight, Body)
01/2019 - 01/2003
4Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
04/2012 - 06/2010
3Residual Neoplasm
12/2019 - 04/2005
3Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
11/2016 - 05/2010
3Stomach Neoplasms (Stomach Cancer)
01/2016 - 10/2014

Drug/Important Bio-Agent (IBA)

65Monoclonal AntibodiesIBA
01/2021 - 01/2002
46AntibodiesIBA
06/2015 - 05/2002
45Peptides (Polypeptides)IBA
01/2021 - 05/2002
39Carcinoembryonic AntigenIBA
01/2021 - 02/2002
38AntigensIBA
01/2020 - 01/2002
36Radioisotopes (Radionuclides)IBA
01/2017 - 05/2002
35Immunoconjugates (Immunoconjugate)IBA
01/2021 - 11/2003
30epratuzumabIBA
01/2018 - 01/2003
28Immunoglobulin G (IgG)IBA
09/2019 - 04/2002
26HaptensIBA
02/2015 - 09/2003
22Irinotecan (Camptosar)FDA LinkGeneric
01/2021 - 04/2005
19sacituzumab govitecanIBA
01/2021 - 05/2015
18veltuzumabIBA
11/2016 - 04/2004
17Pharmaceutical PreparationsIBA
01/2020 - 01/2002
16Proteins (Proteins, Gene)FDA Link
01/2016 - 09/2003
15Rituximab (Mabthera)FDA Link
12/2014 - 04/2004
13milatuzumabIBA
01/2021 - 12/2004
12AcidsIBA
01/2017 - 09/2003
12Bispecific AntibodiesIBA
02/2015 - 05/2002
10Pentetic Acid (DTPA)FDA LinkGeneric
09/2019 - 01/2003
10HLA-DR Antigens (HLA-DR)IBA
01/2018 - 01/2005
101,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2017 - 01/2003
9DOTA- tyrosyl- lysyl(histaminyl- succinyl- glycyl)- glutamyl- lysyl(histaminyl- succinyl- glycyl)amideIBA
01/2021 - 04/2010
8Biomarkers (Surrogate Marker)IBA
10/2020 - 12/2007
8Histamine (Histamine Dihydrochloride)FDA Link
09/2019 - 11/2005
8Glycine (Aminoacetic Acid)FDA LinkGeneric
09/2019 - 11/2005
7GemcitabineFDA Link
01/2021 - 11/2004
7labetuzumabIBA
02/2017 - 12/2004
6Doxorubicin (Adriamycin)FDA LinkGeneric
06/2013 - 04/2005
5Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2020 - 10/2006
5MucinsIBA
09/2015 - 12/2009
5clivatuzumabIBA
02/2015 - 12/2009
5EpitopesIBA
02/2015 - 10/2005
4Surface Antigens (Surface Antigen)IBA
01/2021 - 05/2002
4DNA (Deoxyribonucleic Acid)IBA
10/2020 - 07/2012
4ProdrugsIBA
01/2020 - 11/2008
4procaine isothiocyanate (PRIT)IBA
01/2017 - 11/2010
4CytokinesIBA
10/2014 - 05/2002
4Biological ProductsIBA
03/2014 - 04/2005
4EnzymesIBA
02/2013 - 01/2006
4Immunotoxins (Immunotoxin)IBA
07/2012 - 05/2005
4IsotopesIBA
06/2012 - 11/2003
4Ribonucleases (Ribonuclease)IBA
08/2010 - 05/2002
4Complement System Proteins (Complement)IBA
05/2010 - 04/2004
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2007 - 04/2002
4Immunoglobulin Fab FragmentsIBA
05/2006 - 04/2002
3Topoisomerase I InhibitorsIBA
01/2021 - 11/2008
3Immunoglobulins (Immunoglobulin)IBA
08/2019 - 10/2010
3labetuzumab govitecanIBA
01/2018 - 06/2015
3Messenger RNA (mRNA)IBA
01/2016 - 04/2002
3YttriumIBA
09/2015 - 01/2003
3Dexamethasone (Maxidex)FDA LinkGeneric
04/2015 - 04/2009
3Therapeutic UsesIBA
12/2012 - 09/2003
3Calcitonin (Calcitonin, Eel)FDA LinkGeneric
08/2012 - 06/2012
3Humanized Monoclonal AntibodiesIBA
10/2010 - 05/2005
3SphingomyelinsIBA
06/2009 - 02/2002
3CeramidesIBA
06/2009 - 11/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2007 - 04/2002
3IodineIBA
06/2005 - 03/2004

Therapy/Procedure

109Therapeutics
03/2020 - 02/2002
71Radioimmunotherapy
02/2017 - 01/2002
24Drug Therapy (Chemotherapy)
01/2021 - 01/2002
13Immunotherapy
06/2018 - 01/2003
4Computer-Assisted Surgery (Image Guided Surgery)
04/2020 - 09/2014
4Subcutaneous Injections
11/2016 - 05/2010
4Radiotherapy
04/2013 - 05/2005